A double-blind controlled trial of @entity5616 300 mg nocte and @entity5616 150 mg b.i.d. in the short-term treatment of XXXX .

@entity1 @entity5616 @entity2275
A multi-center study was carried out to compare the healing rates of @entity5616 300 mg nocte and 150 mg b.i.d. in the short-term treatment of @entity2275 and to assess the side-effect liability of @entity5616 300 mg given in a single daily dose. Forty-five outpatients suffering from endoscopically and bioptically proven uncomplicated benign @entity2275 were selected for the study. The @entity1 were treated, for 4 weeks, on the basis of a double-blind randomized design. An endoscopic examination was repeated within 4 days after the end of the treatments. The @entity1 who did not demonstrate complete healing were treated for an additional 4-week period. Clinical controls were performed to evaluate symptoms, antacid consumption, compliance with trial tablet consumption; hematological and biochemical tests were also carried out at the end of the 4 and 8-week periods. No differences were observed between the healing rate induced by 300 mg nocte and 150 mg b.i.d., after 4 weeks of treatment (76% and 79% respectively) and after 8 weeks (100% in both groups). Similar results were obtained as far as symptoms, antacid consumption and compliance are concerned. Neither treatment regimen induced appreciable side-effects.
